Literature DB >> 20850938

[Inheritance in erythropoietic protoporphyria].

C Schmitt1, S Ducamp, L Gouya, J-C Deybach, H Puy.   

Abstract

Erythropoietic protoporphyria (EPP) is an inherited disorder of heme biosynthesis that results from an accumulation of protoporphyrin IX in erythroid cells, plasma, skin and liver. EPP leads to acute photosensitivity and, in about 2% of patients, liver disease. EPP is a complex syndrome in which two genes are independently involved: FECH and ALAS2. More than 96% of unrelated EPP patients have ferrochelatase (FECH) deficiency (MIM 177000). Four percent of them present with autosomal recessive inheritance with two mutated FECH alleles. In dominant cases (95%) the inheritance of a common hypomorphic IVS3-48C FECH allele trans to a deleterious FECH mutation reduces FECH activity below a critical threshold. The frequency of the IVS3-48C allele differs widely from the Japanese (45%), to Black West Africans (<1%) populations. These differences in the frequency of this single common SNP account for the prevalence of overt EPP in different countries and for the absence of EPP in Black Africans. The phylogenic origin of the IVS3-48C haplotypes strongly suggests that the IVS3-48C allele arose from a single recent mutational event that occurred 60 Kyears ago. Acquired somatic mutation of FECH secondary to myeloid disease may also exceptionally cause EPP (<1%). Finally, about 4% of unrelated EPP patients have X-linked dominant protoporphyria (XLDPP) (MIM 300752) caused by gain-of-function mutations in the ALAS2 gene leading to an increased erythroid heme biosynthesis and subsequently an accumulation of protoporphyrin without any FECH deficiency.
Copyright © 2010 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20850938     DOI: 10.1016/j.patbio.2010.01.007

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  4 in total

1.  Loss-of-function ferrochelatase and gain-of-function erythroid-specific 5-aminolevulinate synthase mutations causing erythropoietic protoporphyria and x-linked protoporphyria in North American patients reveal novel mutations and a high prevalence of X-linked protoporphyria.

Authors:  Manisha Balwani; Dana Doheny; David F Bishop; Irina Nazarenko; Makiko Yasuda; Harry A Dailey; Karl E Anderson; D Montgomery Bissell; Joseph Bloomer; Herbert L Bonkovsky; John D Phillips; Lawrence Liu; Robert J Desnick
Journal:  Mol Med       Date:  2013-04-30       Impact factor: 6.354

Review 2.  Advances in the management of erythropoietic protoporphyria - role of afamelanotide.

Authors:  Ashley M Lane; Jerome T McKay; Herbert L Bonkovsky
Journal:  Appl Clin Genet       Date:  2016-12-12

3.  Diagnosis of erythropoietic protoporphyria with severe liver injury: A case report.

Authors:  Hui-Min Liu; Guo-Hong Deng; Qing Mao; Xiao-Hong Wang
Journal:  World J Gastroenterol       Date:  2019-02-21       Impact factor: 5.742

4.  The potential role of cell penetrating peptides in the intracellular delivery of proteins for therapy of erythroid related disorders.

Authors:  Lefkothea C Papadopoulou; Asterios S Tsiftsoglou
Journal:  Pharmaceuticals (Basel)       Date:  2013-01-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.